Thyroid disease

Prevalence and Management of Complications of Laser Ablation for Benign Thyroid Nodules

J Clin Endocrinol MetabPublished Systematic review and meta-analysis

Authors' conclusion

LA for benign and noncystic STNs can be considered a generally safe technique. Major complications are rare.

Study context

Population
Benign solid (noncystic) thyroid nodules treated with percutaneous laser ablation38 studies + institutional data
Participants
4,745 participants
Outcome
Prevalence of complications of laser ablation (LA)
Methodological detailsrandom effects meta-analysis, includes author institutional data, Overall quality of included studies judged fair
  • Random effects meta-analysis
  • Includes author institutional data
  • Overall quality of included studies judged fair

Pooled result

As reported in the abstract

Overall complications (1208 of 4702 TNs; I2 93.7%)

23%

CI, 17%–30%

Minor complications (1159 of 4702 TNs; I2 93.7%)

21%

CI, 15%–27%

Major complications (49 of 4745 TNs; I2 54.0%)

2%

CI, 1%–3%

Further pooled results

Sensitivity analyses: dysphonia by anaesthesia type

Dysphonia with local anesthesia (I2 25.2; P = .010)
2% (CI, 1%-3%)
Dysphonia with conscious sedation (I2 27.2; P = .014)
2% (CI, 1%-4%)
Sensitivity analyses did not modify the results, except for dysphonia
  • Pooled prevalence higher with local anesthesia or conscious sedation

Safety

Local pain

Pooled prevalence of local pain (I2 89.3)
15% (CI, 12%-20%)
Transient, typically mild to moderate, sometimes severe; analgesics for 1 to 5 days up to 1 month

Dysphonia

Pooled prevalence of dysphonia (I2 30.3)
2% (CI, 1%-2%)
Permanent dysphonia; all other cases transient
1 case

Original publication

Prevalence and Management of Complications of Laser Ablation for Benign Thyroid Nodules. J Clin Endocrinol Metab. Published 20 February 2025. doi:10.1210/clinem/dgaf108

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.